Product News

Clonmel Healthcare launches Lenalidomide Clonmel

Lenalidomide Clonmel is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma.

clonmel healthcare

Clonmel Healthcare is delighted to announce the launch of Lenalidomide Clonmel 5mg, 10mg, 15mg, 20mg, 25mg hard capsules.

Lenalidomide Clonmel is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free